- active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - recruitingPHASE2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
This study is for people with advanced lung cancer that has spread. It tests new treatments using a drug called Visugromab, combined with Nivolumab and sometimes Docetaxel, to see if they can work better than existing options.
United States · Germany · Italy - recruitingPHASE1
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
This study is testing a new medicine, DO-2, for people with advanced solid tumours, especially lung cancer, that have specific genetic changes and where other treatments haven't worked. It aims to see if DO-2 is safe and how it moves through the body.
Belgium · France · Netherlands